Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review

INTRODUCTION: Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major therapeutic advance over conventional CML therapy, with more than 90% of patients obtaining complete hematologic respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Jabbour, Elias, Cortes, Jorge, Kantarjian, Hagop
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899790/
https://www.ncbi.nlm.nih.gov/pubmed/20694077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899790/
https://www.ncbi.nlm.nih.gov/pubmed/20694077

Ejemplares similares